



Ifw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Confirmation No.: 4282
)	
Kenshi KAMEI et al)	Art Unit: 1614
)	
Appln. No.: 10/532,585)	Examiner: P. G. Spivack
)	
Filing Date: 10/24/2003)	December 8, 2006
371(c) Date: 04/25/2005)	
)	ATTY.'S DOCKET: KAMEI=2
For: THERAPEUTIC AND/OR)	
PREVENTIVE AGENT...)	

SUBMISSION OF CORRECTED FORM PTO-SB/08A/B

Customer Service Window, Mail Stop Amendment
Honorable Commissioner for Patents
U.S. Patent and Trademark Office
Randolph Building, 401 Dulany Street
Alexandria, Virginia 22314

Sir:


An Information Disclosure Statement was submitted on the above-identified application on October 3, 2006. After careful review it was noted that the page number of document "AT" listed in the Form PTO/SB/08A/B should read "pages 830-835" and not 83-835.

Attached is a replacement Form PTO-SB/08A/B correcting this typographical error.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:


Sheridan Neimark
Registration No. 20,520

SN:jec
624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202)628-5197
Facsimile: (202)737-3528

G:\BN\Y\YUAS\Kamei2\Pto\2006-12-08 Corrted 1449.doc



BN/SB/08A/B

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/532,585
		Filing Date	April 25, 2005
		First Named Inventor	K. KAMEI et al
		Group Art Unit	1614
		Confirmation No.	4282
Sheet 1	of 1	Attorney Docket Number	KAMEI=2

NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AK	O. ALARADI et al; "Irritable bowel syndrome: update on pathogenesis and management"; <i>Med Principles Pract</i> ; Vol. 11, page 2-17, 2002.	
	AL	M. BRADETTE, et al; "Effect of motilin and erythromycin on the motor activity of the human colon"; <i>J. Gastrointest. Mot.</i> , Vol. 5, pages 247-251, 1993.	
	AM	D. M. CHIEPPA, et al; Effects of erythromycin on human colonic circular muscle in idiopathic chronic constipation"; <i>European Journal of Clinical Investigation</i> ; Vol. 30, pages 66-71, 2000.	
	AN	D. HARARI et al; "Correlates of regular laxative use by frail elderly persons"; <i>The American Journal of Medicine</i> , Vol. 99, pp. 513-518,	
	AO	Zen ITOH; "Motilin and Clinical Application"; <i>Peptides</i> , Vol. 18, No. 4, pages 593-608, 1997.	
	AP	J. S. JAMESON et al; "Oral or intravenous erythromycin has no effect on human distal colonic motility"; <i>Aliment, Pharmacol. Ther.</i> , Vol. 6, pages 589-595, 1992.	
	AQ	I.M.C. KAMERLING et al; "Dose-related effects of motilin on proximal gastrointestinal motility"; <i>Ailment Pharmacol Ther</i> ; Vol. 16, pages 129-135, 2002.	
	AR	I.M.C. KAMERLING et al; "Exogenous motilin affects postprandial proximal gastric motor function and visceral sensation"; <i>Digestive Diseases and Sciences</i> ; Vol. 47, No. 8, pages 1732-1736, 2002.	
	AS	H. KOGA et al; "Design, SAR and pharmacology of GM-611, the first acid-stable non-peptide motilin receptor agonist"; <i>Drugs of the Future</i> ; Vol. 27, No. 3; pages 255-272, 2002.	
	AT	Y.C. LUIKING et al; "Motilin induces gall bladder emptying and antral contractions in the fasted state in humans"; <i>Gut</i> ; Vol. 42, pages 830-835, 1998.	
	AU	M. PAPPAGALLO; "Incidence, Prevalence, and Management of Opioid Bowel Dysfunction"; <i>The American Journal of Surgery</i> ; Vol. 182, pages 11S-18S; 2001.	
	AV	S. SHARMA et al "Effect of oral erythromycin on colonic transit in patients with idiopathic constipation"; <i>Digestive Diseases and Sciences</i> , Vol. 40, No. 11, pages 2446-2449, 1995.	
	AW	D. THORPE; "Management of Opioid-induced Constipation"; <i>Curr. Pain Headache Rep.</i> , Vol. 5, pages 237-240, 2001.	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.